Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center
Background: Head-and-neck squamous cell cancers (HNSCC) are common in India. Recurrent and metastatic HNSCC carry a poor prognosis. The chemotherapy options are limited, and the median survival is measured in months. The addition of targeted antibodies and immunotherapy improves overall survival (OS...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Cancer Research, Statistics, and Treatment |
| Subjects: | |
| Online Access: | http://www.crstonline.com/article.asp?issn=2590-3233;year=2022;volume=5;issue=4;spage=630;epage=637;aulast=Sarma |
| _version_ | 1797866707630424064 |
|---|---|
| author | Rup J Sarma Vijay M Patil Alok Shetty Nandini Menon Vanita Noronha Kumar Prabhash |
| author_facet | Rup J Sarma Vijay M Patil Alok Shetty Nandini Menon Vanita Noronha Kumar Prabhash |
| author_sort | Rup J Sarma |
| collection | DOAJ |
| description | Background: Head-and-neck squamous cell cancers (HNSCC) are common in India. Recurrent and metastatic HNSCC carry a poor prognosis. The chemotherapy options are limited, and the median survival is measured in months. The addition of targeted antibodies and immunotherapy improves overall survival (OS). In resource-limited settings, chemotherapy remains the only option in advanced HNSCC.
Objectives: We aimed to assess the efficacy and safety of the combination of paclitaxel and Mycidac-C (heat-killed Mycobacterium w) in the palliative setting for advanced HNSCC.
Materials and Methods: This was a retrospective study conducted in the Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India in patients with relapsed/refractory or metastatic HNSCC who received the combination of paclitaxel and Mycidac-C between August 2019 and May 2020. Patients were treated until progression or unacceptable toxicity. The study was approved by the Institutional Ethics Committee, and the requirement for written informed consent was waived.
Results: We included 28 patients in the study. Most of the patients (22, 78.6%) had oral cavity cancers and had platinum-refractory disease (25 patients, 96.4%). The median age was 51 years (range, 31-70), 26 (92.9%) patients were male, and 25 (89.3%) had a performance status of 0-1. At least two lines of previous therapies had been administered to 23 (82.1%) patients. The median duration of follow-up was 3.4 months (range, 0.2-18.1). The median numbers of cycles of paclitaxel and Mycidac-C administered were 3 (range, 1-6) and 2.5 (range, 1-6), respectively. The median progression-free survival (PFS) and OS were 2.9 months (95% confidence interval [CI], 2.36-3.48) and 4.9 months (95% CI, 3.78-5.99), respectively. The most common adverse effects were anemia in 26 (93.9%) patients and increased alanine aminotransferase and aspartate aminotransferase levels in five (17.9%) and four (14.3%) patients, respectively. Four (14.3%) patients developed neutropenia, two (7.1%) developed diarrhea, and two (7.1%) developed peripheral neuropathy.
Conclusion: In resource-limited settings, the combination of paclitaxel and Mycidac-C can be considered a therapeutic option for patients with advanced relapsed/metastatic HNSCC. |
| first_indexed | 2024-04-09T23:29:44Z |
| format | Article |
| id | doaj.art-72fc2e58d90b45958ac60040c8898fc8 |
| institution | Directory Open Access Journal |
| issn | 2590-3233 2590-3225 |
| language | English |
| last_indexed | 2024-04-09T23:29:44Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Cancer Research, Statistics, and Treatment |
| spelling | doaj.art-72fc2e58d90b45958ac60040c8898fc82023-03-21T07:28:38ZengWolters Kluwer Medknow PublicationsCancer Research, Statistics, and Treatment2590-32332590-32252022-01-015463063710.4103/crst.crst_203_22Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer centerRup J SarmaVijay M PatilAlok ShettyNandini MenonVanita NoronhaKumar PrabhashBackground: Head-and-neck squamous cell cancers (HNSCC) are common in India. Recurrent and metastatic HNSCC carry a poor prognosis. The chemotherapy options are limited, and the median survival is measured in months. The addition of targeted antibodies and immunotherapy improves overall survival (OS). In resource-limited settings, chemotherapy remains the only option in advanced HNSCC. Objectives: We aimed to assess the efficacy and safety of the combination of paclitaxel and Mycidac-C (heat-killed Mycobacterium w) in the palliative setting for advanced HNSCC. Materials and Methods: This was a retrospective study conducted in the Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India in patients with relapsed/refractory or metastatic HNSCC who received the combination of paclitaxel and Mycidac-C between August 2019 and May 2020. Patients were treated until progression or unacceptable toxicity. The study was approved by the Institutional Ethics Committee, and the requirement for written informed consent was waived. Results: We included 28 patients in the study. Most of the patients (22, 78.6%) had oral cavity cancers and had platinum-refractory disease (25 patients, 96.4%). The median age was 51 years (range, 31-70), 26 (92.9%) patients were male, and 25 (89.3%) had a performance status of 0-1. At least two lines of previous therapies had been administered to 23 (82.1%) patients. The median duration of follow-up was 3.4 months (range, 0.2-18.1). The median numbers of cycles of paclitaxel and Mycidac-C administered were 3 (range, 1-6) and 2.5 (range, 1-6), respectively. The median progression-free survival (PFS) and OS were 2.9 months (95% confidence interval [CI], 2.36-3.48) and 4.9 months (95% CI, 3.78-5.99), respectively. The most common adverse effects were anemia in 26 (93.9%) patients and increased alanine aminotransferase and aspartate aminotransferase levels in five (17.9%) and four (14.3%) patients, respectively. Four (14.3%) patients developed neutropenia, two (7.1%) developed diarrhea, and two (7.1%) developed peripheral neuropathy. Conclusion: In resource-limited settings, the combination of paclitaxel and Mycidac-C can be considered a therapeutic option for patients with advanced relapsed/metastatic HNSCC.http://www.crstonline.com/article.asp?issn=2590-3233;year=2022;volume=5;issue=4;spage=630;epage=637;aulast=Sarmahead and neck cancerhnsccoral cancerplatinum refractory |
| spellingShingle | Rup J Sarma Vijay M Patil Alok Shetty Nandini Menon Vanita Noronha Kumar Prabhash Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center Cancer Research, Statistics, and Treatment head and neck cancer hnscc oral cancer platinum refractory |
| title | Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center |
| title_full | Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center |
| title_fullStr | Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center |
| title_full_unstemmed | Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center |
| title_short | Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center |
| title_sort | paclitaxel with mycidac c in the second line and beyond in advanced head and neck cancer a retrospective analysis from a tertiary cancer center |
| topic | head and neck cancer hnscc oral cancer platinum refractory |
| url | http://www.crstonline.com/article.asp?issn=2590-3233;year=2022;volume=5;issue=4;spage=630;epage=637;aulast=Sarma |
| work_keys_str_mv | AT rupjsarma paclitaxelwithmycidaccinthesecondlineandbeyondinadvancedheadandneckcanceraretrospectiveanalysisfromatertiarycancercenter AT vijaympatil paclitaxelwithmycidaccinthesecondlineandbeyondinadvancedheadandneckcanceraretrospectiveanalysisfromatertiarycancercenter AT alokshetty paclitaxelwithmycidaccinthesecondlineandbeyondinadvancedheadandneckcanceraretrospectiveanalysisfromatertiarycancercenter AT nandinimenon paclitaxelwithmycidaccinthesecondlineandbeyondinadvancedheadandneckcanceraretrospectiveanalysisfromatertiarycancercenter AT vanitanoronha paclitaxelwithmycidaccinthesecondlineandbeyondinadvancedheadandneckcanceraretrospectiveanalysisfromatertiarycancercenter AT kumarprabhash paclitaxelwithmycidaccinthesecondlineandbeyondinadvancedheadandneckcanceraretrospectiveanalysisfromatertiarycancercenter |